National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideBronwen E. Shaw, Javier Bolaños‐Meade, Xiao-Ying Tang et al.|Journal of Clinical Oncology|2021Cited by 217
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E. Shaw, Javier Bolaños‐Meade, Antonio Martin Jimenez-Jimenez et al.|Transplantation and Cellular Therapy|2022Cited by 55
Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) InitiativeBronwen E. Shaw, Javier Bolaños‐Meade, Antonio Martin Jimenez-Jimenez et al.|Blood|2020Cited by 7
Transplantation Using Bone Marrow from a (very) HLA Mismatched Unrelated Donor in the Setting of Post-Transplant Cyclophosphamide Is Feasible and Expands Access to Underserved MinoritiesBronwen E. Shaw, F. Javier Bolaños-Meade, Steven M. Devine et al.|Transplantation and Cellular Therapy|2020Cited by 2